Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 2
2006 2
2009 1
2010 3
2012 1
2013 2
2016 1
2018 2
2019 4
2021 1
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T, Reich K, Paul C, Tsunemi Y, Augustin M, Lacour JP, Ghislain PD, Dutronc Y, Liao R, Yang FE, Brinker D, DeLozier AM, Meskimen E, Janes JM, Eyerich K; BREEZE-AD4 study group. Bieber T, et al. Br J Dermatol. 2022 Sep;187(3):338-352. doi: 10.1111/bjd.21630. Epub 2022 Jul 20. Br J Dermatol. 2022. PMID: 35484697 Clinical Trial.
Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE).
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B. de Bruin-Weller M, et al. Br J Dermatol. 2018 May;178(5):1083-1101. doi: 10.1111/bjd.16156. Epub 2018 Mar 25. Br J Dermatol. 2018. PMID: 29193016 Free article. Clinical Trial.
Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants.
Gäckler A, Dolff S, Rohn H, Korth J, Wilde B, Eisenberger U, Mitchell A, Kribben A, Witzke O. Gäckler A, et al. BMC Nephrol. 2019 May 14;20(1):167. doi: 10.1186/s12882-019-1340-z. BMC Nephrol. 2019. PMID: 31088392 Free PMC article. Clinical Trial.
Copenhagen Head Injury Ciclosporin Study: A Phase IIa Safety, Pharmacokinetics, and Biomarker Study of Ciclosporin in Severe Traumatic Brain Injury Patients.
Kelsen J, Karlsson M, Hansson MJ, Yang Z, Fischer W, Hugerth M, Nordström CH, Åstrand R, Keep MF, Kilbaugh T, Wang KKW, Møller K, Juhler M, Elmér E. Kelsen J, et al. J Neurotrauma. 2019 Dec 1;36(23):3253-3263. doi: 10.1089/neu.2018.6369. Epub 2019 Aug 1. J Neurotrauma. 2019. PMID: 31210099 Free PMC article. Clinical Trial.
Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.
Leonardi A, Messmer EM, Labetoulle M, Amrane M, Garrigue JS, Ismail D, Sainz-de-la-Maza M, Figueiredo FC, Baudouin C. Leonardi A, et al. Br J Ophthalmol. 2019 Jan;103(1):125-131. doi: 10.1136/bjophthalmol-2017-311801. Epub 2018 Mar 15. Br J Ophthalmol. 2019. PMID: 29545413 Free PMC article. Clinical Trial.
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
19 results